• FDA lifts clinical hold, clearing uniQure to resume hemophilia gene therapy trial

    10 days ago - By MedCity News

    A uniQure gene therapy for hemophilia B that has been under a clinical hold for four months can now resume testing. The hold was lifted after uniQure answered the FDA's questions about whether the gene therapy caused the liver cancer diagnosed in one patient who received the therapy.
    Read more ...